CN100341507C - Compound bergenin pills and its preparation method - Google Patents
Compound bergenin pills and its preparation method Download PDFInfo
- Publication number
- CN100341507C CN100341507C CNB2004100796525A CN200410079652A CN100341507C CN 100341507 C CN100341507 C CN 100341507C CN B2004100796525 A CNB2004100796525 A CN B2004100796525A CN 200410079652 A CN200410079652 A CN 200410079652A CN 100341507 C CN100341507 C CN 100341507C
- Authority
- CN
- China
- Prior art keywords
- bergeninum
- medicine
- chlorphenamine
- pharmaceutic adjuvant
- active constituents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a novel medical preparation for treating chronic bronchitis, common cold and cough and a preparation method thereof. A compound bergeninum drop pill of the present invention is prepared from medical active ingredients and medical auxiliary material, wherein the medical active ingredients contain bergeninum and chlortrimeton. According to the weight percentage, the novel medical preparation contains the following ingredients: 8 to 42% of bergeninum, 0.001 to 0.01% of chlortrimeton and the medical auxiliary material as the rest. The present invention changes the dispersed state of the medicine by changing the preparation, the composition, the technical process, etc., the medicine dissolution is enhanced, and therefore, the biological availability is enhanced.
Description
Technical field
The present invention relates to this medicine of a kind of medicine for the treatment of chronic bronchitis and cold cough, especially novel form and preparation method thereof.
Background technology
Bergeninum is a kind of extract of plant amedica, has the effect of relieving cough and expelling phlegm, can be used for treating chronic bronchitis.Curative effect can be affirmed, but onset time is slower.Main cause is that Bergeninum is a poorly water soluble drugs, and it is slow to make tablet stripping in human body with general disintegrating process, and bioavailability is low, thereby influences the performance of optimal efficacy.Therefore the bioavailability that how to improve behind the Bergeninum preparation oral is an important difficult problem in this field, is not resolved as yet so far.
Summary of the invention
The objective of the invention is to overcome the deficiencies in the prior art, a kind of oral back dissolution height is provided, bioavailability is compound bergenin pills preferably.
Another object of the present invention provides the preparation method of this compound bergenin pills.
Compound bergenin pills of the present invention is made up of active constituents of medicine and pharmaceutic adjuvant, described active constituents of medicine is Bergeninum and chlorphenamine, and its percentage by weight is: Bergeninum 8-42%, chlorphenamine 0.001-0.01%, surplus are pharmaceutic adjuvant.
Above-mentioned Bergeninum claims bergenin again, is the active ingredient of extracting from saxifragaceae plant Rhizoma Seu Herba Bergeniae BergmiaPurpurascens (Hook.f.et.Thoms.) Engl. or Yunnan Rhizoma Seu Herba Bergeniae Bergmia Purpurascens (Hook.f.et.Thoms.) Engl.Vardelavayi (Franch) Engl.etirm rhizome.Bergeninum and chlorphenamine are prior art.
Above-mentioned pharmaceutic adjuvant is Polyethylene Glycol (PEG) 6000, Polyethylene Glycol (PEG) 4000, lecithin (PC).Can be wherein one or more.
The preparation method of compound bergenin pills of the present invention is divided into two kinds of fusion method and solvent methods.
The preparation method of compound bergenin pills of the present invention is made up of following steps:
One, gets the abundant mixing of Bergeninum, chlorphenamine and pharmaceutic adjuvant, put in 60 ℃-95 ℃ the water-bath fully thermosol;
Two, pour in the drop pill organizational security temperature charging apparatus, 60 ℃-90 ℃ of holding temperatures splash in the condensed fluid with per minute 40-90,5 ℃-16 ℃ of condensate temperatures;
Three, drip off the back and with filter paper the condensing agent of drop pill surface attachment inhaled and gone, put in the baking oven in 30 ℃-45 ℃ dry 12-24 hour, get product after the packing.
Above-mentioned condensed fluid is liquid Paraffin, vegetable oil, methyl-silicone oil etc.
The preparation method of compound bergenin pills of the present invention is made up of following steps:
One, gets Bergeninum and chlorphenamine, add in 60 ℃ of-80 ℃ of ethanol and dissolve, treat that medicine is all molten intact;
Two, get it filled and pour in the above-mentioned solution with adjuvant, the limit edged is stirred to dissolving fully, reclaims ethanol to there not being the alcohol flavor;
Three, pour in the drop pill organizational security temperature charging apparatus, 60 ℃-90 ℃ of holding temperatures splash in the condensed fluid with per minute 40-90,5 ℃-16 ℃ of condensate temperatures;
Four, drip off the back and with filter paper the condensing agent of drop pill surface attachment inhaled and gone, put in the baking oven in 30 ℃-45 ℃ dry 12-24 hour, get product after the packing.
Above-mentioned concentration of alcohol is 75%-95%, and its addition is Bergeninum and chlorphenamine 10-30 a times.Above-mentioned condensed fluid is liquid Paraffin, vegetable oil, methyl-silicone oil etc.
It is very close with the dispersity relation of medicine that solution of the present invention is based on the release-absorption of insoluble drug in the pharmaceutical preparation, very big to its medicine absorption in vivo influence, with the dispersity powder that general breaking method makes, often bioavailability is lower in vivo.This just need reach the purpose that improves bioavailability by changing the dispersity that methods such as dosage form, composition and technical process change medicine.
The present invention is exactly by changing dosage form, add macromolecule carrier (substrate), change preparation process, utilize solid dispersion technology, improve the dissolution of Bergeninum, improving its bioavailability in vivo.The dispersion technology of solid drugs, particularly insoluble drug when solid dispersion technology is meant the preparation preparation.Solid dispersion is meant the medicine high degree of dispersion in carrier, forms a kind of disperse system that exists with solid form.Insoluble drug is dispersed in the solid dispersion that obtains medicine-carrier in the carrier of a kind of no physiologically active (water soluble polymer substrate) by certain method, medicine is superfine colloid and ultrafine dust in solid dispersion, even molecularity exists.
Study of pharmacy and part pharmacological research:
1, the present invention and compound bergenin pills dissolution contrast test
Compound bergenin pills (Kunming biological preparation factory, lot number: 20020201) dissolution (%) measurement result:
| Time | Measure number of times | Date processing | |||||
| T (branch) | 1 | 2 | 3 | 4 | 5 | X | SD |
| 3 | 39.6 | 43.2 | 28.8 | 32.4 | 18 | 32.4 | 9.8590 |
| 5 | 46.8 | 72 | 54 | 57.6 | 32.4 | 52.56 | 14.5343 |
| 8 | 61.2 | 57.6 | 61.2 | 61.2 | 46.8 | 57.6 | 7.2000 |
| 10 | 60.15 | 75 | 46.8 | 72 | 46.8 | 60.15 | 15.4638 |
| 15 | 64.2 | 79.2 | 68.4 | 68.4 | 61.8 | 68.28 | 6.8200 |
| 20 | 72 | 82.8 | 79.2 | 82.8 | 68.4 | 77.04 | 6.5397 |
| 30 | 87.3 | 86.4 | 108 | 86.4 | 68.4 | 87.3 | 16.2000 |
| 45 | 82.8 | 86.4 | 79.2 | 86.4 | 75.6 | 82.08 | 4.6938 |
| 60 | 72 | 90 | 72 | 97.2 | 67.5 | 79.74 | 13.0360 |
Dissolution of the present invention (%) measurement result:
| Time | Measure number of times | Date processing | |||||
| T (branch) | 1 | 2 | 3 | 4 | 5 | X | SD |
| 3 | 18 | 32.4 | 25.2 | 10.2 | 28.8 | 28.8 | 8.8832 |
| 5 | 43.2 | 46.8 | 57.6 | 39.6 | 57.6 | 48.96 | 8.2878 |
| 8 | 72 | 79.2 | 86.4 | 64.8 | 82.8 | 77.04 | 8.6699 |
| 10 | 104.4 | 93.6 | 86.4 | 86.4 | 90 | 92.16 | 7.4651 |
| 15 | 93.6 | 97.2 | 100.8 | 86.4 | 97.2 | 95.04 | 5.4597 |
| 20 | 108 | 101.6 | 108 | 93.6 | 97.2 | 101.68 | 6.4274 |
| 30 | 104.4 | 82.8 | 97.2 | 90 | 100.8 | 95.04 | 8.6699 |
| 45 | 111.6 | 82.8 | 108 | 104.4 | 100.8 | 101.52 | 11.2121 |
| 60 | 90 | 109.6 | 100.8 | 100.8 | 97.2 | 99.68 | 7.0846 |
Above compound bergenin pills, five dissolutions of compound bergenin pills (%) meansigma methods are carried out date processing with weighted least-squares method, calculate T50, the Td of compound bergenin pills and compound bergenin pills, the dissolution time of T70, T80 respectively:
The result shows that dissolution of the present invention is better and complete than compound bergenin pills.
2, the present invention and compound bergenin pills bioavailability contrast test
Method according to the pharmacopeia regulation, carry out the present invention and compound bergenin pills (Kunming biological preparation factory with rat, lot number: 20020201) Isodose contrast test, as testing index, the result shows that bioavailability of the present invention is than compound bergenin pills height with Bergeninum (the Chinese biological goods are identified the 1532-200202 of institute).
3, the present invention and compound bergenin pills (Kunming biological preparation factory, lot number 20020201) cough-relieving test
Method: get white mice, body weight 18-22g is divided into blank group, positive administration group, the basic, normal, high dosage group of the present invention, compound bergenin pills group at random.Behind the gastric infusion 1 hour, place strong aqua ammonia to draw mice and cough in the device, make mice quantitatively regularly suck strong aqua ammonia and cause and cough, observe mouse cough number of times in the incubation period and 3 minutes that begins to occur coughing, the result adopts the t check to handle relatively:
| Group | Number of animals (only) | Dosage (mg/Kg) | The cough number of times | Cough latent period (second) |
| The blank group | 20 | 31.6±15.86 | 39.2±18.77 | |
| Carbetapentane citrate tablet | 10 | 20 | 15.4±7.38 | 66.95±32.5 |
| Compound bergenin pills | 10 | 80.4 | 20.2±8.84 | 55.1±21.36 |
| The drop pill low dosage | 20 | 40.2 | 17.2±12.33 | 54±26.26 |
| Dosage in the drop pill | 20 | 80.4 | 15.70±11.6 | 54.15±21.48 |
| The drop pill high dose | 10 | 160.8 | 13.50±5.78 | 64.8±25.36 |
Show that antitussive action of the present invention is better than compound bergenin pills.
The specific embodiment
Embodiment 1: get 30 parts of Bergeninums, and 0.48 part of chlorphenamine, 269.52 parts of PEG6000 promptly get every drop pill finished product that contains the plain 3mg of Rhizoma Seu Herba Bergeniae by above-mentioned fusion legal system.
Embodiment 2: get 45 parts of Bergeninums, and 0.72 part of chlorphenamine, 254.28 parts of PEG4000 promptly get every drop pill finished product that contains the plain 4.5mg of Rhizoma Seu Herba Bergeniae by above-mentioned fusion legal system.
Embodiment 3: get 60 parts of Bergeninums, and 0.96 part of chlorphenamine, 239.04 parts of PEG6000 promptly get every drop pill finished product that contains the plain 6mg of Rhizoma Seu Herba Bergeniae by above-mentioned fusion legal system.
Embodiment 4: get 75 parts of Bergeninums, and 1.2 parts of chlorphenamines, 223.8 parts of PEG4000 promptly get every drop pill finished product that contains the plain 7.5mg of Rhizoma Seu Herba Bergeniae by above-mentioned fusion legal system.
Embodiment 5: get 90 parts of Bergeninums, and 1.44 parts of chlorphenamines, 208.56 parts of PEG6000 promptly get every drop pill finished product that contains the plain 9mg of Rhizoma Seu Herba Bergeniae by above-mentioned fusion legal system.
Embodiment 6: get 105 parts of Bergeninums, and 1.68 parts of chlorphenamines, 193.32 parts of PEG4000 promptly get every drop pill finished product that contains the plain 10.5mg of Rhizoma Seu Herba Bergeniae by above-mentioned solvent legal system.
Embodiment 7: get 120 parts of Bergeninums, and 1.92 parts of chlorphenamines, 178.08 parts of PEG6000 promptly get every drop pill finished product that contains the plain 12mg of Rhizoma Seu Herba Bergeniae by above-mentioned solvent legal system.
Embodiment 8: get 90 parts of Bergeninums, and 1.44 parts of chlorphenamines, 104.28 parts of PEG6000,104.28 parts of PEG4000 promptly get every drop pill finished product that contains the plain 9mg of Rhizoma Seu Herba Bergeniae by above-mentioned solvent legal system.
Embodiment 9: get 105 parts of Bergeninums, and 1.68 parts of chlorphenamines, 32.22 parts of PEG6000,161.10 parts of PEG4000 promptly get every drop pill finished product that contains the plain 10.5mg of Rhizoma Seu Herba Bergeniae by above-mentioned solvent legal system.
Embodiment 10: get 120 parts of Bergeninums, and 1.92 parts of chlorphenamines, 4,000 176.18 parts of PEG, 1.9 parts of PC promptly get every drop pill finished product that contains the plain 12mg of Rhizoma Seu Herba Bergeniae by above-mentioned solvent legal system.
Content of the present invention is not limited to embodiment.
Claims (12)
1, a kind of compound bergenin pills, it is characterized in that forming by active constituents of medicine and pharmaceutic adjuvant, described active constituents of medicine is Bergeninum and chlorphenamine, and its percentage by weight is: Bergeninum 10%, chlorphenamine 0.16%, surplus are pharmaceutic adjuvant.
2, a kind of compound bergenin pills, it is characterized in that forming by active constituents of medicine and pharmaceutic adjuvant, described active constituents of medicine is Bergeninum and chlorphenamine, and its percentage by weight is: Bergeninum 15%, chlorphenamine 0.24%, surplus are pharmaceutic adjuvant.
3, a kind of compound bergenin pills, it is characterized in that forming by active constituents of medicine and pharmaceutic adjuvant, described active constituents of medicine is Bergeninum and chlorphenamine, and its percentage by weight is: Bergeninum 20%, chlorphenamine 0.32%, surplus are pharmaceutic adjuvant.
4, a kind of compound bergenin pills, it is characterized in that forming by active constituents of medicine and pharmaceutic adjuvant, described active constituents of medicine is Bergeninum and chlorphenamine, and its percentage by weight is: Bergeninum 25%, chlorphenamine 0.40%, surplus are pharmaceutic adjuvant.
5, a kind of compound bergenin pills, it is characterized in that forming by active constituents of medicine and pharmaceutic adjuvant, described active constituents of medicine is Bergeninum and chlorphenamine, and its percentage by weight is: Bergeninum 30%, chlorphenamine 0.48%, surplus are pharmaceutic adjuvant.
6, a kind of compound bergenin pills, it is characterized in that forming by active constituents of medicine and pharmaceutic adjuvant, described active constituents of medicine is Bergeninum and chlorphenamine, and its percentage by weight is: Bergeninum 35%, chlorphenamine 0.56%, surplus are pharmaceutic adjuvant.
7, a kind of compound bergenin pills, it is characterized in that forming by active constituents of medicine and pharmaceutic adjuvant, described active constituents of medicine is Bergeninum and chlorphenamine, and its percentage by weight is: Bergeninum 40%, chlorphenamine 0.64%, surplus are pharmaceutic adjuvant.
8,, it is characterized in that described pharmaceutic adjuvant is polyethylene glycol 6000, Macrogol 4000, lecithin according to any described compound bergenin pills of claim 1-7.
9,, it is characterized in that forming by following steps according to the preparation method of any described compound bergenin pills of claim 1-7:
One, gets the abundant mixing of Bergeninum, chlorphenamine and pharmaceutic adjuvant, put in 60 ℃-95 ℃ the water-bath fully thermosol;
Two, pour in the drop pill organizational security temperature charging apparatus, 60 ℃-90 ℃ of holding temperatures splash in the condensed fluid with per minute 40-90,5 ℃-16 ℃ of condensate temperatures;
Three, drip off the back and with filter paper the condensing agent of drop pill surface attachment inhaled and gone, put in the baking oven in 30 ℃-45 ℃ dry 12-24 hour, get product after the packing.
10,, it is characterized in that described condensed fluid is liquid Paraffin, vegetable oil, methyl-silicone oil according to the preparation method of the described compound bergenin pills of claim 9.
11,, it is characterized in that forming by following steps according to the preparation method of any described compound bergenin pills of claim 1-7:
One, gets Bergeninum and chlorphenamine, add in 60 ℃ of-80 ℃ of ethanol and dissolve, treat that medicine is all molten intact;
Two, get it filled and pour in the above-mentioned solution with adjuvant, the limit edged is stirred to dissolving fully, reclaims ethanol to there not being the alcohol flavor;
Three, pour in the drop pill organizational security temperature charging apparatus, 60 ℃-90 ℃ of holding temperatures splash in the condensed fluid with per minute 40-90,5 ℃-16 ℃ of condensate temperatures;
Four, drip off the back and with filter paper the condensing agent of drop pill surface attachment inhaled and gone, put in the baking oven in 30 ℃-45 ℃ dry 12-24 hour, get product after the packing.
12,, it is characterized in that described condensed fluid is liquid Paraffin, vegetable oil, methyl-silicone oil according to the preparation method of the described compound bergenin pills of claim 11.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100796525A CN100341507C (en) | 2004-12-31 | 2004-12-31 | Compound bergenin pills and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100796525A CN100341507C (en) | 2004-12-31 | 2004-12-31 | Compound bergenin pills and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1799544A CN1799544A (en) | 2006-07-12 |
| CN100341507C true CN100341507C (en) | 2007-10-10 |
Family
ID=36809904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100796525A Expired - Fee Related CN100341507C (en) | 2004-12-31 | 2004-12-31 | Compound bergenin pills and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100341507C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105832752A (en) * | 2016-04-08 | 2016-08-10 | 王金霞 | Pharmaceutical composition for clinical nursing of upper respiratory infection |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06100640A (en) * | 1992-09-22 | 1994-04-12 | Kansai Paint Co Ltd | Actinic-radiation-during colored coating composition for vacuum-formable film, vacuum-formable film and vacuum-formed article |
-
2004
- 2004-12-31 CN CNB2004100796525A patent/CN100341507C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06100640A (en) * | 1992-09-22 | 1994-04-12 | Kansai Paint Co Ltd | Actinic-radiation-during colored coating composition for vacuum-formable film, vacuum-formable film and vacuum-formed article |
Non-Patent Citations (3)
| Title |
|---|
| 复方岩白菜素栓剂的研制 关家彦，高晓黎，阿力木江，肖克来提，中成药，第10期 1998 * |
| 复方岩白菜素片中两种主要成分的含量测定 郭炎荣，蒙大平，中国药业，第11卷第8期 2002 * |
| 岩白菜素固体分散物的研究 孙殿甲，崔玉琴，邹小广，陈刚，中成药研究，第3期 1987 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1799544A (en) | 2006-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lu et al. | Sucrose acetate isobutyrate as an in situ forming system for sustained risperidone release | |
| Fang et al. | Characterizing the release mechanism of donepezil-loaded PLGA microspheres in vitro and in vivo | |
| CN106265641A (en) | A kind of pharmaceutical composition containing vildagliptin and metformin and preparation method thereof | |
| CN1762401A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN103356491A (en) | Preparation method of syringopicroside (SYR) poly(lactide-co-glycolide) (PLGA) nanoparticles | |
| CN100341507C (en) | Compound bergenin pills and its preparation method | |
| CN106727362A (en) | A kind of Triptorelin microballoon and preparation method and application | |
| Jaiswal et al. | Design and development of valsartan loaded nanostructured lipid carrier for the treatment of diabetic wound healing | |
| CN102552165B (en) | Sarpogrelate hydrochloride sustained release pellet and preparation method thereof | |
| CN1698591A (en) | Ginger phenols extract microcapsule and preparation method thereof | |
| CN107362142A (en) | A kind of fulvestrant lipidosome injection and preparation method thereof | |
| CN1442145A (en) | Aspilrin slow release tablet | |
| CN1250216C (en) | Medication for treating acute hepatitis and chronic hepatitis and preparation technique | |
| Yadav et al. | Encapsulation of repaglinide into eudragit RS microspheres and modulation of their release characteristics by use of surfactants | |
| CN1299667C (en) | Nano Chinese medicine threewingnut/Tripterygium prepn and its prepn process | |
| CN1259099C (en) | Prepared traditional Chinese drug Liangfu drop pills for treating epigastric pain | |
| CN113164395A (en) | Long-acting naltrexone microparticle composition for injection | |
| CN107669720A (en) | Compound ginseng ganoderma spove powder micro-capsule and preparation method thereof | |
| CN1883601A (en) | Chinese medicinal capsule for treating inflammation and method for preparing same | |
| Sravya et al. | Formulation and Evaluation of Posaconazole Bilayer Delayed Release Tablets Using Solid Dispersion Technique | |
| CN1872179A (en) | Microspheres in use for injection of Chinese traditional medicine of containing astragalus root, and preparation method | |
| CN1939323A (en) | Bean-curd fruit aglycone preparation and its making method | |
| CN103976957A (en) | 20 (S)-protopanaxadiol microsphere and preparation method and application thereof | |
| CN1241556C (en) | Emodin injection preparation and its preparation method | |
| CN1242742C (en) | Oryzanol containing soft capsule preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071010 Termination date: 20201231 |